{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:25:04Z","timestamp":1790036704187,"version":"4.0.1"},"reference-count":60,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1016\/j.vaccine.2009.12.062","type":"journal-article","created":{"date-parts":[[2010,1,6]],"date-time":"2010-01-06T10:13:55Z","timestamp":1262772835000},"page":"2330-2339","source":"Crossref","is-referenced-by-count":67,"title":["Rift Valley fever virus subunit vaccines confer complete protection against a lethal virus challenge"],"prefix":"10.1016","volume":"28","author":[{"given":"S.M.","family":"de Boer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Kortekaas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.F.","family":"Antonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Kant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.L.","family":"van Oploo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.J.M.","family":"Rottier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.J.M.","family":"Moormann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.J.","family":"Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Dec 1 (47)","key":"10.1016\/j.vaccine.2009.12.062_bib1","first-page":"1065","article-title":"Outbreak of Rift Valley fever \u2013 Yemen, August\u2013October 2000","volume":"49","author":"CDC","year":"2000","journal-title":"Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2009.12.062_bib2","first-page":"413","article-title":"Rift Valley fever: a review","volume":"5","author":"Weiss","year":"1957","journal-title":"Bull Epizootic Dis Africa"},{"issue":"November 3 (44)","key":"10.1016\/j.vaccine.2009.12.062_bib3","first-page":"797","article-title":"Rift valley fever. I. The occurrence of human cases in Johannesburg","volume":"25","author":"Mundel","year":"1951","journal-title":"S Afr Med J"},{"issue":"November 15 (20)","key":"10.1016\/j.vaccine.2009.12.062_bib4","first-page":"803","article-title":"Rift Valley fever in humans in South Africa","volume":"58","author":"McIntosh","year":"1980","journal-title":"S Afr Med J"},{"issue":"February 2 (4)","key":"10.1016\/j.vaccine.2009.12.062_bib5","first-page":"73","article-title":"Rift Valley fever outbreak \u2013 Kenya, November 2006\u2013January 2007","volume":"56","author":"CDC","year":"2007","journal-title":"Morb Mortal Wkly Rep"},{"issue":"May 18 (20)","key":"10.1016\/j.vaccine.2009.12.062_bib6","first-page":"169","article-title":"Outbreaks of Rift Valley fever in Kenya, Somalia and United Republic of Tanzania. December 2006\u2013April 2007","volume":"82","author":"WHO","year":"2007","journal-title":"Wkly Epidemiol Rec"},{"issue":"November 30 (48)","key":"10.1016\/j.vaccine.2009.12.062_bib7","first-page":"417","article-title":"Outbreak news. Rift Valley fever, Sudan\u2014update","volume":"82","author":"WHO","year":"2007","journal-title":"Wkly Epidemiol Rec"},{"issue":"May 21 (8)","key":"10.1016\/j.vaccine.2009.12.062_bib8","first-page":"157","article-title":"Outbreak news. Rift Valley fever, Madagascar","volume":"83","author":"WHO","year":"2008","journal-title":"Wkly Epidemiol Rec"},{"issue":"May (4)","key":"10.1016\/j.vaccine.2009.12.062_bib9","doi-asserted-by":"crossref","first-page":"647","DOI":"10.3201\/eid1204.051120","article-title":"Animals as sentinels of bioterrorism agents","volume":"12","author":"Rabinowitz","year":"2006","journal-title":"Emerg Infect Dis"},{"issue":"May (18)","key":"10.1016\/j.vaccine.2009.12.062_bib10","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1001\/jama.287.18.2391","article-title":"Hemorrhagic fever viruses as biological weapons","volume":"287","author":"Borio","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2009.12.062_bib11","series-title":"Fields Virology","first-page":"695","article-title":"Bunyaviridae: the viruses and their replication","author":"Schmaljohn","year":"2001"},{"issue":"January 20 (2)","key":"10.1016\/j.vaccine.2009.12.062_bib12","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.virol.2006.08.002","article-title":"Synthesis, proteolytic processing and complex formation of N-terminally nested precursor proteins of the Rift Valley fever virus glycoproteins","volume":"357","author":"Gerrard","year":"2007","journal-title":"Virology"},{"issue":"April (8)","key":"10.1016\/j.vaccine.2009.12.062_bib13","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1128\/JVI.02483-08","article-title":"Electron cryo-microscopy and single-particle averaging of Rift Valley fever virus: evidence for GN\u2013GC glycoprotein heterodimers","volume":"83","author":"Huiskonen","year":"2009","journal-title":"J Virol"},{"issue":"December (23)","key":"10.1016\/j.vaccine.2009.12.062_bib14","doi-asserted-by":"crossref","first-page":"12200","DOI":"10.1128\/JVI.76.23.12200-12210.2002","article-title":"Characterization of the Golgi retention motif of Rift Valley fever virus G(N) glycoprotein","volume":"76","author":"Gerrard","year":"2002","journal-title":"J Virol"},{"issue":"November (21)","key":"10.1016\/j.vaccine.2009.12.062_bib15","doi-asserted-by":"crossref","first-page":"10341","DOI":"10.1128\/JVI.01191-08","article-title":"Three-dimensional organization of Rift Valley fever virus revealed by cryoelectron tomography","volume":"82","author":"Freiberg","year":"2008","journal-title":"J Virol"},{"issue":"May 1","key":"10.1016\/j.vaccine.2009.12.062_bib16","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/0042-6822(89)90365-6","article-title":"Baculovirus expression of the M genome segment of Rift Valley fever virus and examination of antigenic and immunogenic properties of the expressed proteins","volume":"170","author":"Schmaljohn","year":"1989","journal-title":"Virology"},{"issue":"March 15 (2)","key":"10.1016\/j.vaccine.2009.12.062_bib17","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.virol.2008.12.012","article-title":"Vaccination with virus-like particles protects mice from lethal infection of Rift Valley fever virus","volume":"385","author":"Naslund","year":"2009","journal-title":"Virology"},{"issue":"November 23","key":"10.1016\/j.vaccine.2009.12.062_bib18","article-title":"A replication-incompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challenge","author":"Mandell","year":"2009","journal-title":"Virology"},{"issue":"May 22 (21)","key":"10.1016\/j.vaccine.2009.12.062_bib19","doi-asserted-by":"crossref","first-page":"4657","DOI":"10.1016\/j.vaccine.2005.08.034","article-title":"Immunogenicity of combination DNA vaccines for Rift Valley fever virus, tick-borne encephalitis virus, Hantaan virus, and Crimean Congo hemorrhagic fever virus","volume":"24","author":"Spik","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.12.062_bib20","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1743-422X-6-6","article-title":"Characterisation of immune responses and protective efficacy in mice after immunisation with Rift Valley Fever virus cDNA constructs","volume":"6","author":"Lagerqvist","year":"2009","journal-title":"Virol J"},{"issue":"November 30 (49\u201350)","key":"10.1016\/j.vaccine.2009.12.062_bib21","doi-asserted-by":"crossref","first-page":"7181","DOI":"10.1016\/j.vaccine.2006.06.041","article-title":"Protective immune responses induced by different recombinant vaccine regimes to Rift Valley fever","volume":"24","author":"Wallace","year":"2006","journal-title":"Vaccine"},{"issue":"September (9)","key":"10.1016\/j.vaccine.2009.12.062_bib22","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1017\/S0950268808001696","article-title":"An alphavirus replicon-derived candidate vaccine against Rift Valley fever virus","volume":"137","author":"Heise","year":"2009","journal-title":"Epidemiol Infect"},{"issue":"February (1)","key":"10.1016\/j.vaccine.2009.12.062_bib23","first-page":"1","article-title":"Rift Valley fever; the neurotropic adaptation of the virus and the experimental use of this modified virus as a vaccine","volume":"30","author":"Smithburn","year":"1949","journal-title":"Br J Exp Pathol"},{"issue":"October","key":"10.1016\/j.vaccine.2009.12.062_bib24","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1099\/0022-1317-66-10-2271","article-title":"Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development","volume":"66","author":"Caplen","year":"1985","journal-title":"J Gen Virol"},{"issue":"October (4)","key":"10.1016\/j.vaccine.2009.12.062_bib25","doi-asserted-by":"crossref","first-page":"405","DOI":"10.4269\/ajtmh.1995.53.405","article-title":"Characterization of clone 13, a naturally attenuated avirulent isolate of Rift Valley fever virus, which is altered in the small segment","volume":"53","author":"Muller","year":"1995","journal-title":"Am J Trop Med Hyg"},{"issue":"March (6)","key":"10.1016\/j.vaccine.2009.12.062_bib26","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1128\/JVI.02501-07","article-title":"Rift valley fever virus lacking the NSs and NSm genes is highly attenuated, confers protective immunity from virulent virus challenge, and allows for differential identification of infected and vaccinated animals","volume":"82","author":"Bird","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2009.12.062_bib27","unstructured":"Pittman PR. Safety and immunogenicity of live-attenuated MP-12 Rift Valley fever vaccine (ZH548, MP-12, TSI-GSD-223 Lot 7-2-88) in humans, and genetic characterization of virus isolates recovered from the blood of vaccinated volunteers: a phase II study. Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00415051."},{"issue":"August 20 (1\u20132)","key":"10.1016\/j.vaccine.2009.12.062_bib28","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0264-410X(99)00218-2","article-title":"Immunogenicity of an inactivated Rift Valley fever vaccine in humans: a 12-year experience","volume":"18","author":"Pittman","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.12.062_bib29","doi-asserted-by":"crossref","unstructured":"Bouloy M, Flick R. Reverse genetics technology for Rift Valley fever virus: current and future applications for the development of therapeutics and vaccines. 2009;84(November (2)):101\u2013118 [Epub 2009 August 12].","DOI":"10.1016\/j.antiviral.2009.08.002"},{"issue":"January\u2013February (1)","key":"10.1016\/j.vaccine.2009.12.062_bib30","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4161\/hv.4.1.5559","article-title":"Virus-like particles as a vaccine delivery system: myths and facts","volume":"4","author":"Roy","year":"2008","journal-title":"Hum Vaccine"},{"key":"10.1016\/j.vaccine.2009.12.062_bib31","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1146\/annurev.immunol.15.1.235","article-title":"Neutralizing antiviral B cell responses","volume":"15","author":"Bachmann","year":"1997","journal-title":"Annu Rev Immunol"},{"issue":"March 15 (2)","key":"10.1016\/j.vaccine.2009.12.062_bib32","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.virol.2008.12.011","article-title":"Efficient production of Rift Valley fever virus-like particles: the antiviral protein MxA can inhibit primary transcription of bunyaviruses","volume":"385","author":"Habjan","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2009.12.062_bib33","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/1743-422X-5-82","article-title":"Rift Valley fever virus structural proteins: expression, characterization and assembly of recombinant proteins","volume":"5","author":"Liu","year":"2008","journal-title":"Virol J"},{"issue":"October (2\u20133)","key":"10.1016\/j.vaccine.2009.12.062_bib34","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0168-1702(95)00053-S","article-title":"Nucleocapsid- and virus-like particles assemble in cells infected with recombinant baculoviruses or vaccinia viruses expressing the M and the S segments of Hantaan virus","volume":"38","author":"Betenbaugh","year":"1995","journal-title":"Virus Res"},{"issue":"November (21)","key":"10.1016\/j.vaccine.2009.12.062_bib35","doi-asserted-by":"crossref","first-page":"10428","DOI":"10.1128\/JVI.01362-06","article-title":"Generation and analysis of infectious virus-like particles of uukuniemi virus (bunyaviridae): a useful system for studying bunyaviral packaging and budding","volume":"80","author":"Overby","year":"2006","journal-title":"J Virol"},{"issue":"December 15 (2)","key":"10.1016\/j.vaccine.2009.12.062_bib36","first-page":"193","article-title":"Efficient selection for high-expression transfectants with a novel eukaryotic vector","volume":"108","author":"Niwa","year":"1991","journal-title":"Gene"},{"issue":"December 5\u201320 (1\u20132)","key":"10.1016\/j.vaccine.2009.12.062_bib37","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.virol.2006.07.035","article-title":"Development and characterization of a Rift Valley fever virus cell\u2013cell fusion assay using alphavirus replicon vectors","volume":"356","author":"Filone","year":"2006","journal-title":"Virology"},{"issue":"April (2)","key":"10.1016\/j.vaccine.2009.12.062_bib38","first-page":"353","article-title":"Cell lines derived from late embryonic stages of Drosophila melanogaster","volume":"27","author":"Schneider","year":"1972","journal-title":"J Embryol Exp Morphol"},{"issue":"June (6)","key":"10.1016\/j.vaccine.2009.12.062_bib39","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1101\/gad.3.6.882","article-title":"Regulated expression at high copy number allows production of a growth-inhibitory oncogene product in Drosophila Schneider cells","volume":"3","author":"Johansen","year":"1989","journal-title":"Genes Dev"},{"issue":"August (16)","key":"10.1016\/j.vaccine.2009.12.062_bib40","doi-asserted-by":"crossref","first-page":"8801","DOI":"10.1128\/JVI.77.16.8801-8811.2003","article-title":"The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex","volume":"77","author":"Bosch","year":"2003","journal-title":"J Virol"},{"issue":"September (1\u20132)","key":"10.1016\/j.vaccine.2009.12.062_bib41","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0165-2427(94)05413-M","article-title":"Comparison of adjuvants for immune potentiating properties and side effects in mice","volume":"48","author":"Leenaars","year":"1995","journal-title":"Vet Immunol Immunopathol"},{"issue":"February 5 (1\u20132)","key":"10.1016\/j.vaccine.2009.12.062_bib42","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.vetmic.2007.07.031","article-title":"Recombinant nucleocapsid-based ELISA for detection of IgG antibody to Rift Valley fever virus in African buffalo","volume":"127","author":"Paweska","year":"2008","journal-title":"Vet Microbiol"},{"key":"10.1016\/j.vaccine.2009.12.062_bib43","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/BF01863914","article-title":"Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche","volume":"162","author":"K\u00e4rber","year":"1931","journal-title":"Arch Exp Path Pharmak"},{"key":"10.1016\/j.vaccine.2009.12.062_bib44","first-page":"227","article-title":"The method of \u201cright and wrong cases\u201d (\u201cconstant stimuli\u201d) without Gauss's formulae","volume":"2","author":"Spearman","year":"1908","journal-title":"Br J Psychol"},{"issue":"July (7)","key":"10.1016\/j.vaccine.2009.12.062_bib45","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1128\/JCM.40.7.2323-2330.2002","article-title":"Rapid detection and quantification of RNA of Ebola and Marburg viruses, Lassa virus, Crimean-Congo hemorrhagic fever virus. Rift Valley fever virus, dengue virus, and yellow fever virus by real-time reverse transcription-PCR","volume":"40","author":"Drosten","year":"2002","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2009.12.062_bib46","series-title":"Fields virology","first-page":"1476","article-title":"Bunyaviridae","author":"Gonzalez-Scarano","year":"1996"},{"issue":"September (18)","key":"10.1016\/j.vaccine.2009.12.062_bib47","doi-asserted-by":"crossref","first-page":"12106","DOI":"10.1128\/JVI.79.18.12106-12111.2005","article-title":"Rift Valley fever virus NSs mRNA is transcribed from an incoming anti-viral-sense S RNA segment","volume":"79","author":"Ikegami","year":"2005","journal-title":"J Virol"},{"issue":"2\u20133","key":"10.1016\/j.vaccine.2009.12.062_bib48","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0147-9571(86)90008-1","article-title":"The influence of a water-in-oil emulsion on humoral immunity","volume":"9","author":"Bokhout","year":"1986","journal-title":"Comp Immunol Microbiol Infect Dis"},{"issue":"February 14 (9\u201310)","key":"10.1016\/j.vaccine.2009.12.062_bib49","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/S0264-410X(02)00552-2","article-title":"Investigation of several selected adjuvants regarding their efficacy and side effects for the production of a vaccine for parakeets to prevent a disease caused by a paramyxovirus type 3","volume":"21","author":"Beck","year":"2003","journal-title":"Vaccine"},{"issue":"January 6 (11\u201312)","key":"10.1016\/j.vaccine.2009.12.062_bib50","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/S0264-410X(99)00351-5","article-title":"HPV6b virus like particles are potent immunogens without adjuvant in man","volume":"18","author":"Zhang","year":"2000","journal-title":"Vaccine"},{"issue":"May\u2013June (3)","key":"10.1016\/j.vaccine.2009.12.062_bib51","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/clinids\/2.3.370","article-title":"Vaccine adjuvants","volume":"2","author":"Edelman","year":"1980","journal-title":"Rev Infect Dis"},{"issue":"November (11)","key":"10.1016\/j.vaccine.2009.12.062_bib52","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1002\/eji.1830261118","article-title":"Partial correction of the TH2\/TH1 imbalance in neonatal murine responses to vaccine antigens through selective adjuvant effects","volume":"26","author":"Barrios","year":"1996","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2009.12.062_bib53","unstructured":"Alley R, Berntsen T, Bindoff NL, Chen Z, Chidthaisong A, Friedlingstein P, et al. IPCC WGI fourth assessment report: climate change 2007: the physical science basis: WMO and UNEP; 2007."},{"issue":"October (2)","key":"10.1016\/j.vaccine.2009.12.062_bib54","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1017\/S0022172400065414","article-title":"Comparison of techniques for demonstrating antibodies to Rift Valley fever virus","volume":"97","author":"Swanepoel","year":"1986","journal-title":"J Hyg (Lond)"},{"key":"10.1016\/j.vaccine.2009.12.062_bib55","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1742-4682-1-10","article-title":"Proteomics computational analyses suggest that the carboxyl terminal glycoproteins of Bunyaviruses are class II viral fusion protein (beta-penetrenes)","volume":"1","author":"Garry","year":"2004","journal-title":"Theor Biol Med Model"},{"issue":"1\u20134","key":"10.1016\/j.vaccine.2009.12.062_bib56","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/BF01316748","article-title":"Topological mapping of antigenic sites on the Rift Valley fever virus envelope glycoproteins using monoclonal antibodies","volume":"121","author":"Besselaar","year":"1991","journal-title":"Arch Virol"},{"issue":"1\u20134","key":"10.1016\/j.vaccine.2009.12.062_bib57","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF01309641","article-title":"The synergistic neutralization of Rift Valley fever virus by monoclonal antibodies to the envelope glycoproteins","volume":"125","author":"Besselaar","year":"1992","journal-title":"Arch Virol"},{"issue":"1 (September 15)","key":"10.1016\/j.vaccine.2009.12.062_bib58","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.virol.2007.04.014","article-title":"Comparative analysis of the alphavirus-based vectors expressing Rift Valley fever virus glycoproteins","volume":"366","author":"Gorchakov","year":"2007","journal-title":"Virology"},{"issue":"January 5 (3)","key":"10.1016\/j.vaccine.2009.12.062_bib59","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.vaccine.2006.08.018","article-title":"Preparation and immunogenic properties of a recombinant West Nile subunit vaccine","volume":"25","author":"Lieberman","year":"2007","journal-title":"Vaccine"},{"issue":"July","key":"10.1016\/j.vaccine.2009.12.062_bib60","article-title":"Immunogenicity and protective efficacy of a recombinant subunit West Nile virus vaccine in rhesus monkeys","volume":"29","author":"Lieberman","year":"2009","journal-title":"Clin Vaccine Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X09019793?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X09019793?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T23:26:25Z","timestamp":1558740385000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X09019793"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":60,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["S0264410X09019793"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2009.12.062","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}